rises to delayed, prolonged and increased pain (spinal wind up). 4, 5, 6 Opioids stimulate presynaptic m and k receptors on these axons which inhibit the release of the stimulatory neurotransmitters. 7, 8, 9 Ketamine is a non-competitive antagonist at NMDA-receptors 10 and is analgesic in subanaesthetic doses.
Morphine remains the gold standard for analgesia against which the effectiveness of newer drugs and combinations are measured. It has been the standard analgesic for many years, and the effects of newer analgesics are often expressed in terms of the effect of morphine. The search for good analgesics should not only focus on analgesia. As far as analgesia is concerned, morphine is an excellent drug, but morphine lacks quality of analgesia due to its side effects. These side effects include sedation, respiratory suppression, nausea and vomiting, and pruritis. These side effects may be avoided or reduced by the co-administration of other analgesics, e.g. ketamine.
Apart from postoperative analgesia, ketamine has found application in other fields of analgesia. An oral ketamine suspension has been found superior to a paracetamol-codeine-diphenhydramine suspension as analgesic and sedative for wound care procedures in children. 1 Oral ketamine may also have potential in the treatment of neuropathic pain, including stump pain. 2 The effect of co-administered drugs depends on pharmacodynamic (agonism or antagonism) and pharmacokinetic interactions. When drugs with the same end point (analgesia) affect different receptors, they may be synergistic. C and Aδ fibres conduct nociceptive stimuli to the cell bodies in dorsal ganglia. Axons from these cells release glutamate, aspartate, and substance P. These neurotransmitters stimulate N-methyl-D-aspartate (NMDA) receptors on the cell bodies in the dorsal horn this and gives Postoperatively patients received morphine 30 µg/kg (Group M) or morphine 10 µg/kg plus ketamine 20 µg/kg (Group MK) every 10 minutes until they were pain free. PCA consisted of a bolus of morphine 21 µg/kg (Group M) or morphine 7 µg/kg plus ketamine 14 µg/kg (Group MK); the lock out time was 7 minutes in both groups. No other analgesics were allowed.
The following measurements were made: Sufentanil dose, morphine consumption during the first and second 24 hours, number of PCA requests, pain score (Visual Analogue Pain Score, VAPS), verbal descriptive sedation score (VDSS), haemoglobin saturation on the pulse oximeter at room air (SpO 2 ), respiratory rate (RR). These were done preoperatively and 1, 4, 24 and 48 hours postoperatively.
Statistics
Null hypothesis: The quality of analgesia provided by morphine or low dose morphine plus ketamine do not differ. The response variable was the VAPS. Calculation of the sample size made use of the expected variation (standard deviation = total variation/6), i.e. the range of pain associated with the different treatments. For a standard deviation of 10 mm, resulting from a expected pain range of 60 mm, and an equivalence delta of 10 mm, a sample size of 36 subjects has a power of 80% at the significance level of 0,05.
All continuous variables were analysed using the Student t test for unequal variance (Welch). Discrete variables were analysed using Fischers exact test. Testing was done at the 0,05 level of significance. At each point in time (1, 4, 24 and 48 hours) Groups M and MK were compared with respect to the continuous variables VAPS, SpO 2 , and RR, using analysis of covariance (ANCOVA) with morphine consumption in the appropriate 24 hour period and VAPS as covariates. SpO 2 and RR were analysed with VAPS as the covariate. Equivalence of the two groups was assessed by comparing the 95% confidence interval (CI) for the effect with the equivalence delta (10%).
Results
There was no significant difference between Group M and MK in age (39,33 years vs. 39,39 years; p = 0,9781), body mass (72.06 kg vs. 73,39; p = 0,7786), duration of surgery (102,50 min vs. 100,56 min; p = 0,8476) and sufentanil dose (0,189 µg/kg vs. 0,205 µg/kg; p = 0,5269).
Group MK used significantly less morphine than Group M during the first 24 hours (623,83 µg/kg vs. 885 µg/kg; p = 0,0316), as well as during the second 24 hours (264,89; 413,44; p = 0,0373). The morphine dose in both groups was significantly higher during the first than during the second 24 hour period (p < 0,001). The total number of boluses was significantly higher in Group MK than in Group M (394,5 vs. 156,5; p = 0,0057). Within the groups, there were significant differences in the number of boluses between the first and second 24 hours (p < 0,001) (Table 1, Figure 1) .
In both groups, the mean pain scores (mean of VAPS at rest and during movement) were the highest at 1 hour. The mean VAPS did not differ significantly between groups at 1, 24 and 48 hours, but was significantly lower in Group M than in Group MK at 4 hours (22,36 mm vs. 38,33 mm; p = 0,0113). Although VAPS was not statistically significantly different between groups at 1, 24, and 48 hours, the criterion for equivalence (10%) was not reached. If the equivalence delta is set at 15%, pain scores were nearly equivalent at 24 hours and at 48 hours (Table 1, Figure 1 ). In Group M the pain score was significantly lower at 4 hours than 1 hour (p = 0,0128), but in Group MK the pain scores did not differ between 1 hour and 4 hours (p = 0,7035). In both groups, pain scores decreased after 1 hour with scores signifi- 
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cantly lower at 24 hours than at 4 hours and at 48 hours significantly lower than at 24 hours. In both groups pain scores were still significantly higher at 48 hours than preoperatively (p < 0,05). In neither Group M nor Group MK was any significant correlation (Spearman) found between VAPS at 1, 4 and 24 hours, and the number of boluses during the first 24 hours, or between VAPS at 48 hours and the number of boluses during the second 24 hours. The number of boluses was significantly higher in Group MK during both the first and second 24 hours( Table 1) . As the number of boluses determine the morphine consumption, the contribution of ketamine to analgesia must be determined, i.e. would the number of boluses differ had the bolus in both groups contained the same morphine dose? In order to investigate the influence of ketamine on pain scores at each of the postoperative times, ANCOVA was used with morphine consumption, adjusted for the first (754,86 µg/kg) and second 24 hours (340,67 µg/kg) as covariates. With ANCOVA, the mean VAPS at 4 hours was still significantly higher in Group MK than in Group (36,94 mm vs. 23,23,75; p = 0,0450). Apart from VAPS at 4 hours, the therapies may be regarded as equi-analgesic ( Table 2) .
The SpO 2 and respiratory rate was higher in Group MK throughout the postoperative period. The only difference that was marginally statistically significant, was SpO 2 at 4 hours postoperatively (90,78% vs. 94,17%; p = 0,0809). The SpO 2 readings fell within the equivalence delta of 10%. The lowest SpO 2 occurred at 4 hours and 24 hours (Table 1, Figure 2 ). In order to investigate the influence of ketamine on SpO 2 and respiratory rate at each of the postoperative times, ANCOVA was used with the morphine consumption adjusted for the first (754,86 µg/kg) and second 24 hours (340,67 µg/kg), as well as for the VAPS at 1 hour (33,33 mm), 4 hours (30,34 mm), 24 hours (21,32 mm) and 48 hours (12,50 mm) as covariates. With morphine as covariate, the marginal significant difference in SpO 2 4 hours disappeared (p = 0,2660). With the relevant morphine dose as covariate, the RR at 4 hours was now marginally significantly higher in Group MK (p = 0,0860) but can still be regarded as equal to the RR in Group M (Table 2) . With VAPS as covariate, SpO 2 was always higher in Group MK, but the difference was never statistically significant. Ketamine therefore seems to have had a positive, however no statistically significant effect on SpO 2 . If the patients in the different groups had the same VAPS at the different times, the respiratory rate would also not have differed at any stage. Therefore, with the morphine dose as covariate, the marginally significant difference in SpO 2 between Groups MK and M disappeared but a significant difference in respiratory rate at 4 hours appeared, and with the VAPS as covariate, no significant difference in respiratory rate or SpO 2 between groups was found; the lower dose of morphine and not the amount of pain was therefore probably responsible for the higher respiratory rate and SpO 2 in Group MK. There was no significant difference in sedation scores (VDSS) between groups at any stage. No sedation of VDSS > 2 was observed. No statistical significant difference was detected between groups in the incidence of nausea and vomiting, pruritis or dreaming and hallucinations at any of the times.
Discussion
The choice of doses of combinations of analgesics is hampered by a lack of information regarding interactions (pharmacodynamic and pharmacokinetic) between analgesics. In this study we investigated the analgesic interaction of morphine and ketamine. The VAPS did not reach equivalence (within 10%) at any stage of the study, with Group MK experiencing more pain. The morphine consumption was significantly lower in Group MK: 29% lower in the first 24 hours and 35% lower in the second 24 hours, taking into account that Group MK requested many more boluses during both the first and the second 24 hours. Apart from the significantly higher VAPS in Group MK at 4 hours, the VAPS did not differ significantly (Table 1) . ANCOVA showed that Group MK would experience significantly more pain than Group M at 4 hours, even if they had received the same dose of morphine during the first 24 hours. It thus appears as though ketamine had some anti-analgesic effect at 4 hours ( Table 2) . Using the significance level for statistical significant difference, outcome parameters VAPS, VDSS, SpO 2 , and respiratory rate did not differ between groups (apart from lower VAPS and SpO 2 in Group M at 4 hours), the study partly confirms the null hypothesis, namely that the two PCA techniques are equivalent in the doses used. However, when equivalence of the two groups was assessed using an equivalence delta of 10%, Group M experienced less pain, used more morphine, and less boluses than Group MK, while the side effects did not differ significantly. The two analgesic regimens can therefore, in the doses used, not be regarded equivalent ( Table 1 ).
The number of boluses demanded by patients in Group MK was significantly higher than those in Group M during both the first and the second 24 hours. It may be that the analgesia produced by the lower dose of morphine in Group MK was shorter lived than was the higher dose in Group M. In spite of the significantly higher number of boluses in Group MK, the total dose of morphine was both clinically and statistically lower in Group MK than in Group M. The higher number of boluses in Group MK may be ascribed to amnesia. This might have caused the patient to forget that she had already pushed the button and then would push it again. On the other hand, tolerance to ketamine, or even in these early stages, drug seeking behaviour might have emerged. If the latter had been the case, one would expect the number of demands to increase with time. As this was not the case, the higher number of boluses in Group MK was unlikely to have resulted from the development of tolerance, or drug seeking behaviour.
The total lack of correlation between the VAPS at 1, 4 and 24 hours and the number of boluses during the first 24 hours or the VAPS at 48 and the number of boluses during the second 24 hours casts doubt on the applicability of PCA in the population used (often an inability to communicate due to language barriers). It has been noted that some patients push the button when they think of it, demonstrate it to visitors, etc.
The differences in VAPS and the number of boluses may have been caused by sedation caused by morphine. In this study no difference in sedation was found. The significantly higher number of boluses and VAPS in Group MK might have been caused by subjective side effects (strange feelings) of ketamine -even at analgesic levels. 13 The changes in the morphine dose from the first 24 hours to the second 24 hours was -53,7% in Group M and -57,3% in Group MK (p = 0,7804). This difference was not significant. It is thus unlikely that the morphine sparing effect of ketamine involved the development of tolerance in the short term. The long-term effect of ketamine was not included into this study. It is therefore not possible to draw any conclusion about the possible effect of ketamine on tolerance to opioids. As neither pain scores nor the incidence of side effects differed significantly, it can be concluded that the quality of analgesia rendered by the two techniques was equivalent.
As sole analgesic ketamine is analgesic at about 360 µg/kg/hour and morphine at about 180 µg/kg/hour. If these drugs were synergistic, co-administration of about a third of these doses might have produced adequate analgesia, avoiding their dose dependent side effects. However, if drugs share the same side effect, these side effects may also be more pronounced in combination. Several investigators have studied the co-administration of morphine and ketamine. Subcutaneous ketamine infusion (250 µg/kg followed by 100 µg/kg/hour) provided significantly better quality of analgesia than intravenous morphine (100 µg/kg followed by 100 mg/kg/hour) for the non-surgical care of musculoskeletal trauma. None of the ketamine patients requested additional morphine during treatment of fractures (splinting, manipulation, etc). 14 The superior analgesia provided by the combination of morphine and ketamine reported by Javery et al 15 and Adriaensson et al 16 was achieved at larger doses of morphine and ketamine, namely 100 µg/ kg/hour of each and morphine PCA in combination with a constant ketamine infusion 150 µg/kg/hour respectively. Javery et al used morphine and ketamine in equal doses (100 µg/kg/hour of each). Adriaenssen et al used morphine patient controlled analgesia (1 mg every 8 minutes; maximum of about 70 µg/kg/hour) in combination with a constant ketamine infusion (150 µg/kg/hour). At 1 hour postoperatively the morphine group experienced more pain than the ketamine plus morphine group (5,4 mm vs. 2,5 mm). Although the difference was statistically significant (p < 0,01), we do not regard the difference as clinically of note. The cumulative morphine consumption from 24 hours onward was significantly lower in the morphine-ketamine group. This finding is in accordance with our findings.
Edwards et al investigated the effect of ketamine on analgesia and lung function in elderly patients. They combined morphine PCA infusion of 1 mg/hour (14 µg/kg/hour) with ketamine 5 mg/hour, 10 mg/hour, or 20 mg/hour (54 µg/kg/hour to 468 µg/kg/hour adjusted for body mass). There was an increase in postoperative dreaming but without significant difference in morphine consumption or postoperative analgesia or lung function. No significant correlation was found between the ketamine dose and morphine consumption. 17 Inspection of their data suggests that a substantial number of patients experienced moderate to severe pain at 4 hours and 8 hours postoperatively. It therefore seems that the ketamine doses were too low to add to the analgesia provided by the low dose of morphine (14 µg/kg/hour). Owen et al found that analgesic levels of ketamine (100 µg/l to 150 µg/l 18 ) could be achieved by an infusion of 240 µg/kg/hour.
19 A subcutaneous infusion of morphine 40 µg/kg/hour plus ketamine 600 µg/kg/hour has been found to provide reliable analgesia after abdominal hysterectomy. 20 The question thus arises, whether the maximum doses of morphine and ketamine allowed in Group MK (60 µg/kg/hour and 120 µg/kg/hour respectively) were efficient to ensure adequate analgesia. Taking the findings of previous studies into account, it seems as though the doses of both morphine and ketamine were too low in Group MK. The significant difference in VAPS between MK and M might have been smaller had the morphine and ketamine doses been higher, say in the order of 90 µg/kg/hour and 180 µg/kg/hour respectively (about 11 µg/kg and 22 µg/kg with a lock out period of 7 minutes). These doses represent an additive rather than a synergistic interaction between morphine and ketamine.
Theoretically, any drug with opioid sparing properties may attenuate the development of tolerance. Kissin has shown that ketamine in subanalgesic doses decreased alfentanil consumption in rats. He is of the opinion that ketamine attenuates the development of acute tolerance to alfentanil, as the ketamine dose was too small for any direct antinociceptive action. 21 The effect of ketamine on ventilation is uncertain. Both stimulation 22 as well as depression 23 of ventilation has been reported. In this study ANCOVA revealed that the reason for the difference in respiratory rate at 4 hours can be the presence of ketamine, and that the difference in SpO 2 disappeared if the two groups had received the same dose of morphine. As the morphine consumption was significantly lower in the morphine-ketamine group during the first 24 hours, as well as over 48 hours, while the VAPS did not differ significantly (apart from VAPS at 4 hour), the presence of ketamine in Group MK contributed significantly to analgesia, while attenuating the effect of morphine on SpO 2 and RR.
The effect of ketamine on respiratory rate is in accordance with the findings of Presson et al. 24 They found that analgesic concentrations of ketamine antagonized alfentanil-induced hypoventilation. Alfentanil induced a decrease in respiratory rate, without affecting tidal volume and respiratory drive. They ascribe the effect of ketamine on ventilation to two possible mechanisms. Firstly, ketamine caused subjective side effects in all subjects (e.g. strange feeling, body feels tight, arms and legs strange, body feels heavy, etc) that might have caused general arousal, thereby stimulating respiration indirectly. Secondly, being an NMDA receptor antagonist, ketamine may antagonize the effect of opioids on ventilation as the effect of opioids on the control of breathing may be through inhibition of glutaminergic transmission. 25, 26 No dreaming or hallucinations was reported. The ketamine dose was therefore high enough to have a morphine sparing effect, but lower than a dose that causes hallucinations. It is accepted that affective disturbances may affect pain experience. Subjective side effects of ketamine might have had an influence on the VAPS in this study. Apart from hallucinations, patients were however, not questioned about these side effects. This aspect should be taken into account in studies of this nature.
Conclusion
The low dose ketamine-morphine combination can, in the doses used, not be regarded as equal but rather inferior to morphine PCIA, but it may reduce the profile of respiratory side effects of morphine. The analgesic effects of morphine and ketamine are additive rather than synergistic. In appropriate doses morphine-ketamine combinations may find application in other fields of pain therapy, for example obstetrics and cancer, and deserve further investigation.
